

2nd International Electronic Conference on Medicinal Chemistry

1-30 November 2016 chaired by Dr. Jean Jacques Vanden Eynde

sponsored by
pharmaceuticals

Development of New Aromatic Sulfonamides as Potential Antiglaucoma Agents


Milan Remko^{1,*}, Fridrich Gregáň² ¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia ² Department of Chemistry, Faculty of Natural Sciences, Matej Bel University, 974 01 Banská Bystrica, Slovakia

* Corresponding author: remko@fpharm.uniba.sk





Development of New Aromatic Sulfonamides as Potential Antiglaucoma Agents



Molecular drawing of aromatic sulfonamides studied giving the crystallographic atom-numbering scheme





Abstract: Many sulfonamides with the general formula $R-SO_2NH_2$ constitute an important class of inhibitors of the zinc enzyme carbonic anhydrase (CA) due to their use in antiglaucoma therapy.

Design of new aromatic sulfonamides was carried out using computational methods of theoretical medicinal chemistry as described in our previous works. Of particular interest are the molecular geometries of neutral and anionic species, acidities, and lipophilicities.

Synthesis of the so-designed new aromatic sulfonamides was conducted according to published procedures. Antiglaucoma activity was evaluated in both *in vitro* and *in vivo* conditions. For determination of the intraocular pressure changes the experiment with adult male Chinchilla was used.

In this lecture we present the design and synthesis of novel drug-like aromatic sulfonamides, namely (4-sulfamoyl-N-(3-morpholinopropyl) benzamide, N-(3-morpholinopropyl)benzene-1,4-disulfonamide, N-(4-diethylaminoethoxybenzyl)benzene-1,4-bis(sulfonamide) and their hydrochloride salts. They exhibited favorable biological, structural, physicochemical and some pharmacokinetic properties comparable to those obtained for therapeutically useful acetazolamide, dorzolamide and brinzolamide. Data obtained allows us to assume, that new aromatic sulfonamides may represent novel class of compounds for the discovery of new effective antiglaucoma drugs.

Keywords: sulfonamides; carbonic anhydrase inhibitors, antiglaucoma therapy; physicochemical properties



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016






3

Introduction

It is estimated 2 out of every 100 people over the age of 65 have glaucoma and half of these people don't know it.

(G. H. Cassel, M. D. Billig, H. G. Randall, The Eye Book. The Johns Hopkins University Press. Baltimore, Maryland. 1998.)



Normal Fluid Drainage

Fluid is produced in the ciliary body behind the iris, passes into the front of the eye, and then exits through the drainage canals.

➢In glaucoma, the drainage canals become clogged, blocked, or covered.

➢ Because there is nowhere in the eye for the fluid to go, pressure in the eye increases.

 ➤ When the pressure becomes higher than the optic nerve can tolerate, damage to the optic nerve occurs.
 This damage is called glaucoma.



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:



Carbonic Anhydrase Inhibitors

Carbonic Anhydrases (CAs, EC 4.2.1.1), 14 different isozymes or CA-related proteins (CARP). There are at least five distinct CA families (α , β , γ , δ , and ϵ). Higher Vertebrate a-CA Isozymes

Isozyme	Sub-cellular localization
CAI, CAII, CAIII, CAVII, CARPVIII	Cytosol
CAIV, CAIX, CAXII, CAXIV	Membrane bound
CAV	Mitochondria
CAVI	Secreted into saliva
CARPX, CARPXI, CAXIII	Unknown

Physiologically significant reversible reaction catalysed by a-CA Isozymes

 $H_2O + CO_2 \leftrightarrow H^+ + HCO_3^-$



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:





Sulfonamide Inhibitors of CAs

1940 T. Mann, D. Keilin *Nature*

CA inhibition with sulfanilamide

CA inhibitory properties of sulfonamides

- o Antithyroid drugs
- o Hypoglycemic sulfonamides
- o Antiglaucoma agents
- *o* Novel types of anticancer agents
- o Novel therapy for Alzheimer's disease....


C. T. Supuran, Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nature Rev. Drug Discov. 7 (2008) 168 - 181.*





Sulfonamide Inhibitors of CAs as antiglaucoma agents

•Inhibition of carbonic anhydrase isoforms present in the eyes (CA I, II, IV and XII),



Mincione F, Scozzafava A, Supuran CT, The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.







Design and synthesis of new CA inhibitors

Manual Design

- Operator directs study
- Allows input of designer's ideas
- Useful for identification of a single lead compound
- Slow and limited to designer's originality











Study of Acidity, Lipophilicity and Solubility of Some Biologically **Active Sulfonamides**


Milan Remko, Claus-Wilhelm von der Lieth, 2004 Bioorg. & Med. Chem.





on Medicinal Chemistry 1-30 November 2016





Experimental topically acting antiglaucoma sulfonamides (9 – 13)

Experimental potent cancerostatic sulfonamides (14 – 19)

Structure of the sulfonamides studied




2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:







Structure of the sulfonamides studied



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:





Drug like properties of the sulfonamide inhibitors

The pK_a values of the sulfonamides studied. pK_i and pK_d are corresponding inhibition and dissociation constants against hCA II, respectively

No.	Compound	<i>pKa</i> , calc	<i>pK_{ar}</i> exp	Ref.	р <i>К</i> і, ехр
1	Sulfanilamide	10.1	10.1	35	6.92 ^b
2	Acetazolamide	6.5	7.4	28	8
3	Methazolamide	5.9	7.2	28	8.09
4	Ethoxzolamide	6.8	8.0	28	9.16
5	Dichlorphenamide	7.8	8.3	28	7.52
6	Dansylamide	9.6		21	6.03 ^b
7	Dorzolamide	7.8	8.4	28	8.05
8	Brinzolamide	7.2		28	8.52
9	1I9L	8.8		30	8.62 ^b
10a	A–(R)	9.0		22	10.52 ^b
10b	A–(S)	9.1		22	9.63 ^b
11	В	8.8			
12	С	8.8			
13	D	8.6			
14	IX	17.1 ^a			
15	Х	7.2		31	8.09
16	XI	10.9		32	7.32
17	XII	12.6		32	7.89
18	XIII	9.2		32	7.96
19	E7070	8.5		32	7.82

aUnrecognized functional group, unreliable results ${}^{\mathrm{b}}\mathrm{p}\mathrm{K}_{\mathrm{d}}$ values

•The computed pK_a values correlate well with the available experimental pK_a values found in the literature.

• Aromatic inhibitors 9 – 13 are in the condensed phase by about $1 - 2 pK_a$ units less acidic than heteroaromatic inhibitors (dorzolamide, brinzolamide and compound X).

•The calculations showed that methazolamide is also in water solution the most acidic drug of the sulfonamides investigated. Potent systemic antiglaucoma sulfonamides 2 - 5 are by about 2 - 4 units more acidic than the parent sulfanilamide.





Lipophilicity

No.	Compound	LogP (exp.)	ALOGPs	IA LOGP	CLOGP	KoWWiN
1	Sulfanilamide	-0.62	-0.16	-0.47	-0.57	-0.55
2	Acetazolamide	-0.26	-0.39	-0.25	-0.98	-0.72
3	Methazolamide	0.13	-0.20	-0.08	0.09	0.33
4	Ethoxzolamide	2.01	1.87	2.00	2.05	2.08
5	Dichlorphenamide		0.95	-0.04	0.24	1.06
6	Dansylamide	2.01	1.92	2.07	1.80	1.72
7	Dorzolamide		-0.50	0.71	-0.43	0.37
8	Brinzolamide		-0.65	0.22	0.33	0.33
9	1I9L		1.88	1.67	1.67	1.49
10 a	A–(R)		2.71	2.61	2.83	2.75
10b	A–(S)		2.71	2.61	2.83	2.75
11	В		1.77	1.45	1.39	1.78
12	С		2.53	2.31	2.43	2.33
13	D		2.72	2.26	2.64	1.53
14	IX		0.48	1.66	-0.07	-0.07
15	Х		1.88	1.68	1.37	1.23
16	XI			0.48	1.78	0.88
17	XII			0.22	2.11	0.79
18	XIII			0.10	1.98	1.28
19	E7070		2.22	2.37	2.37	3.53

•The compounds studied are only slightly or moderate lipophilic.

•The lipophilicity of the cancerostatic sulfonamides **14** –**18** is from relatively narrow interval between –0.07 and 1.98.

•The highly active CAI **10** – **13** are also the most lipophilic compounds among the antiglaucomatics studied. Their lipophilicity is considerably higher than the lipophilicity of the clinically useful topically acting antiglaucoma sulfonamides dorzolamide and brinzolamide



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:



Lipinski parameters of the sulfonamides studied

No.	Compound	No. of Hydrogen Bond Acceptors	No. of Hydrogen Bond Donors	log P, calc. ^a	Formula Weight
1	Sulfanilamide	4	4	-0.16 - (-0.57)	172
2	Acetazolamide	7	3	-0.25 - (-0.98)	222
3	Methazolamide	7	2	-0.08 - 0.09	236
4	Ethoxzolamide	5	2	1.87 – 2.08	258
5	Dichlorphenamide	6	4	-0.04 - 1.06	305
6	Dansylamide	4	2	1.72 – 1.92	250
7	Dorzolamide	6	3	-0.43 - 0.71	324
8	Brinzolamide	8	3	-0.65 - 0.33	383
9	1I9L	5	3	1.49 – 1.88	308
10a	A–(R)	6	3	2.15 – 2.83	371
10b	A-(S)	6	3	2.15 – 2.83	371
11	В	5	3	1.39 – 1.78	314
12	С	6	3	1.86 – 2.53	357
13	D	8	4	1.53 – 2.72	381
14	IX	10	3	-0.07 - 1.66	365
15	Х	8	3	1.23 – 1.88	375
16	XI	5	3	0.48 - 1.78	319
17	XII	5	3	0.22 - 2.11	333
18	XIII	5	3	0.10 - 1.98	347
19	E7070	7	4	2.37 – 3.53	385

□ The number of hydrogen bond donors (any NH group) is relatively constant (about 2 –4). Less active ($K_d \approx mM$) sulfanilamide and dansylamide possess substantially less proton accepting sites (any O and N atoms).

□ It is therefore probable that the number of hydrogen bond acceptor groups is one of the important factors for designing of highly–active ($K_d \approx nM$) inhibitors of carbonic anhydrase. However, the possible differences in the nature of the active site of the various CA isoenzymes can also play important part.









Drug like properties of the sulfonamide inhibitors of CAs

Selection criteria for drug-like properties for sulfonamide agents
Molecular weight
Iipophilicity
Acidity and basicity

- ♦ solubility
- ✤polar surface area
- Lipinski parameters

Molecular weight	220 – 400
Octanol/water partition coefficient (clog P)	-0.2 - 2.3
Aqueous solubility (clog S)	(-2) - (-4.5)
рКа	5 – 12.6
No. of hydrogen bond acceptors	4 - 10
No. of hydrogen bond donors	2 – 4
Polar surface area (PSA, Å ²)	80 – 120
Percent of oral absorption (%ABS)	68 – 75







Project

Design, synthesis and testing of new sulfonamide derivatives

About 50 new compounds prepared

➤In vitro tests

≻In vivo tests

$$H_2N-O_2S$$
 $SO_2-NH-(CH_2)_n-R$

$$H_2N-O_2S$$
 CO-X-(CH₂)_n-R

As a prototype of Zn²⁺ ion-coordinated complexes the structure and energetics of 46 species, selected from neutral and charged Lewis bases –irregular substrates of CA– with the zinc cation was examined.

Remko M, Garaj V, Thermodynamics of binding of Zn²⁺ to carbonic anhydrase inhibitors. Mol. Phys. 2003; 101:2357–2368.



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016


sponsors:



Benchmarks

Molecular structure, pK_a , lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides

M. Remko, J. Mol. Struct., Theochem, 2010



Acetazolamide


 $H_5C_{2}^{10}$ $H_5C_{2}^{10}$ NH2 NH2 H₃CO(CH₂), H₃C 0 0 O, Dorzolamide Brinzolamide O 10 10^{-10} 9 O= 0 0= O 5 6NH2 6 NH₂ P10 P20



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:





MDPI

pharmaceuticals

sponsors:

B3LYP/6-311+G(d,p) optimized structures of the sulfonamides investigated



Lipophilicity and Solubility

Drug	LogP (exp.)	ALOGPS	KoWWIN	XLOGP2	LogS (exp.)	AB/logS
Acetazolamide	-0.26	-0.39	-0.72	-0.98	-2.36 (0.98 g/L)	-1.73 (4.14 g/L)
Dorzolamide	-1.0	-0.50	0.37	-0.97		-2.81 (0.50 g/L)
Brinzolamide	-1.8	-0.65	0.33	-1.83		-3.18 (0.25 g/L)
P10		0.39	-0.62	-0.30		-1.64 (7.50 g/L)
P20		-0.23	0.03	-0.86		-1.80 (5.76 g/L)


Calculated partition coefficients and solubilities of the sulfonamides studied

Computed partition coefficients (XLOGP2 method) for drugs studied varied between -0.3 and -1.8.

Compounds are described as slightly lipophilic drugs.

The calculated water solubility of dorzolamide and brinzolamide is comparably low.









Acidity and basicity

The pK_a values of the sulfonamides investigated

Compound	р <i>К_а,</i> ехр	% Ionized form (exp)	p <i>K_{ar}</i> calc		% Ionized	form (calc)
	Acid function ^a	Acid function ^a	Acid function ^a	Basic function ^b	Acid function ^a	Basic function ^b
Acetazolamide	7.4	50	7.3		56	
Dorzolamide	8.4	9	8.4	8.8	9	96
Brinzolamide			8.5	8.8	7	96
P10			9.7	7.4	0.5	50
P20			9.7	7.4	0.5	50

^a sulfonamide ^b amine

The calculated pK_a values of sulfonylamide moiety in the CAI studied are in the range of 7.3 to 9.7 and are characterized as weak organic acids.

Acetazolamide is at physiological pH = 7.4 partially ionized.







Absorption, polar surface area and Rule of Five properties

% ABS = 109 – 0.345 PSA

Y. H. Zhao, M. H. Abraham, J. Lee, A. Hersey, Ch. N. Luscombe, G. Beck, B. Sherborne, I. Cooper, Pharm. Res. 19 (2002) 1446. PSA - the fragment-based method of Ertl and coworkers [P. Ertl, B. Rohde, P. Selzer, J. Med. Chem. 43 (2000) 3714].

Calculated absorption (%ABS), polar surface area (PSA) and Lipinski parameters of the sulfonamides studied

Drug	%ABS	Volume	PSA	NROTB	<i>n</i> ON acceptors	<i>n</i> OHNH donors	Log <i>P</i> , calcd ^a	Formula weight
Acetazolamide	69.3	157.11	115.05	2	7	3	-0.69	222.28
Dorzolamide	72.3	250.85	106.33	3	6	3	-0.37	324.49
Brinzolamide	68.0	306.19	118.81	7	8	3	-0.72	383.57
P10	73.9	286.68	101.73	6	7	3	-0.17	327.45
P20	68.0	299.13	118.81	7	8	3	-0.35	363.51

^aRange of log *P* values obtained by three theoretical methods (ALOGPS, KoWWIN, XLogP2)

Aromatic sulfonamides P10 and P20 exhibit drug-like properties comparable with dorzolamide and/or brinzolamide, and have high probability of being well absorbed.










Synthesis, crystal and molecular structure of two biologically active aromatic sulfonamides and their hydrochloride salts

Milan Remko, Jozef Kožíšek, Jana Semanová, Fridrich Gregáň

J. Mol. Struct. 2010



Details of the three-dimensional hydrogen-bonding network of P10 and P11 with atoms participating in the drawn hydrogen bonds represented by dashed lines.



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:



Synthesis of P 10 and P 11 (the tail approach)

Potassium 4-sulfamoylbenzoate P1, 4-Sulfamoylbenzoyl chloride P2 ÇO₂K ÇO₂H COCI SOCI₂ KHCO₃ SO₂NH₂ SO₂NH₂ SO₂NH₂ A (201.30) P1 (239.20) P2 (219.65) ÇO-NH ÇOCI TEA H_2N THF 4-Sulfamoyl-N- (3-morpholinopropyl) benzamide SO2NH2 SO2NH2 P10 P10 (327.41) P2 (219.65) HCI CO-NH 4-Sulfamoyl-N- (3-morfolinopropyl) CO-NH MeOH benzamide - hydrochloride P11 + HCI SO,NH, SO₂NH₂ "tail" – morpholinopropyl substituent P10 (327.41) P11 (363.86)




2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:




Synthesis of P 30 (I-3), the tail extension strategy



Extended tail of this derivative contains diethylaminoethoxybenzyl moiety and exploit the strategy of enhanced hydrophobic interactions between hydrophobic moieties of both active site of enzyme and inhibitor.







Pharmacology

•In vitro assay – IC₅₀

- •The intraocular pressure changes were evaluated in *in vivo* conditions
- •The laboratory animals of Chinchilla species were used
- •The distilled water was used as a control
- •Measurement apparatus Tono-Pen[®]XL

•For each compound and each concentration 10 independent assays were carried out









Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII

Tab. 1 Biochemical activity IC_{50} (nmol/L) and solubility of the CA inhibitors investigated

Inhibitor	hCA I	hCA II	hCA IV	hCA XII	Solubility
Acetazolamide	250 ^a	12 ^a	70 (bCA IV) ^a		4.14 g/L
Dorzolamide		3.74 ^b	43 ^c		0.50 g/L
Brinzolamide			277.15 ^b		0.25 g/L
I-1	231.4	215.8	611.1	645.2	7.50 g/L
I-2	57.7	65.8	498.8	517.2	5.76 g/L
I-3	59.8	81.1	507.9	736.7	1.63 g/L

C. T. Supuran, A. Maresca, F. Gregáň, M. Remko, Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII, J. Enzym. Inhib. Med. Chem. 28 (2013) 289-293.



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016





In vivo studies, P11

Measured intraocular pressure values [mmHg]

]	N	0.:	5 h	1	h	4	h	7	h	25	h	31	h
n	LE	RE	LE	RE	LE	RE	LE	RE	LE	RE	LE	RE	LE	RE
1	15	14	10	9	9	10	13	11	8	8	12	15	8	9
2	14	15	10	12	12	9	12	10	10	10	13	13	10	16
3	12	12	12	9	18	13	12	13	15	11	13	14	12	13
4	13	14	16	16	13	16	12	11	14	16	13	13	16	15
5	13	16	12	11	8	11	12	9	10	9	13	15	12	12
6	14	16	10	10	9	9	10	10	6	7	12	11	9	9
7	18	17	9	11	11	10	8	8	7	9	10	12	10	9
8	18	18	10	10	10	9	9	9	8	9	13	12	13	10
9	16	15	12	12	9	9	9	9	8	8	13	12	9	9
10	18	16	10	10	11	9	13	11	11	9	13	13	12	10
Average	15.1	15.3	11.1	11	11	10.5	11	10.1	9.7	9.6	12.5	13	11.1	11.2
SD	2.28	1.70	2.02	2.05	2.91	2.32	1.83	1.45	2.95	2.50	0.97	1.33	2.38	2.66
SE ±	0.72	0.54	0.64	0.65	0.92	0.73	0.58	0.46	0.93	0.79	0.31	0.42	0.75	0.84
p(t-test) vs N			0.005	0.000	0.008	0.001	0.003	0.000	0.002	0.000	0.008	0.011	0.003	0.003
p(t-test) L vs R		0.413		0.457		0.338		0.119		0.468		0.175		0.465

Compound I-4, concentration of 2.5%

N-normal value before application

SD-standard deviation

SE—standard error of the average

LE—left eye

RE—right eye



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016

sponsors:





()	Unite Gregan	d States Patent et al.	(10) Patent No.: US 8,193,184 B2 (45) Date of Patent: Jun. 5, 2012
(54)	FOR THE PHARMA	UTED SULPHONAMIDES, PROCESS CIR PREPARATION, CEUTICAL COMPOSITION SING THEREOF AND THEIR USE	C07D 211.22 (2006.01) C07D 211.490 (2006.01) C07D 211.496 (2006.01) 401K 31.798 (2006.01) 401K 31.49 (2006.01)
(75)	Inventors:	Fridrich Gregan, Bratislava (SK); Milan Remko, Bratislava (SK); Elena Sluciakova, Bratislava (SK); Jarmila Knapikova, Bratislava (SK)	A6IK 31/44 (2006.01) A6IK 31/5375 (2006.01) (52) U.S. CL. 514/238.2; 514/428; 514/602 514/603; 514/331; 514/604; 548/82 564/85 564/86; 564/82; 544/159; 546/264; 546/24 564/264/264; 564/28
(73)	Assignce:	Unimed Pharma, SPOL, S.R.O., Bratislava (SK)	(58) Field of Classification Search
(*)	Notice:	Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 291 days.	(56) References Cited FOREIGN PATENT DOCUMENTS WO WO 2006014134 A1 ° 2/2006
(21)	Appl. No.:	12/596,820	* cited by examiner
(22) (86)	PCT Filed PCT No.: § 371 (c)(1	PCT/SK2008/050005	Primary Examiner — Kamal Saeed Assistant Examiner — Michael Barker (74) Attorney, Agent, or Firm — Ohandt, Greeley Ruggiero & Perle, L.L.P.; George W. Rauchfuss, Jr.
	(2), (4) Da		(57) ABSTRACT
(87)		No.: WO2008/130332 Date: Oct. 30, 2008	Substituted sulphonamides having the general formula () and salts, hydrates and solvates thereof were prepared an described, wherein R^1 is CO or SO ₂ and R^2 is NH or O an
(65)		Prior Publication Data	where R represents linear or cyclic aliphatic chain and represents number of linking aliphatic chain carbons (n ca
	US 2010/0	125076 A1 May 20, 2010	be 0, 1, 2 or 3), which are useful in the manufacture of th medicaments due to the carboanhydrase inhibition. Thes
(30)	F	oreign Application Priority Data	compounds are prepared by nucleophilic reaction of an amin with 4-sulfamovlbenzenesulphonyl chloride in the presenc
Aj (51)		(SK) 0054-2007	of triethylamine success in tetrahydrofurane or in ether a temperature 0 to 20° C. The compounds show an antiglauce matic activity.
	C07D 207. C07D 207.		16 Claims, No Drawings

F. Gregáň, M. Remko, E. Slučiaková, J. Knapíková, Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use.

United States Patent 8,193,184 B2. 5 June 2012. Australian Patent No. 2008241590 B2 Jun 21, 2012, Russia Patent No. RU2474574 C2 Feb 10, 2013 European Patent No. EP2142499 (B1) Dec. 10, 2014. Japan Patent 5492764 B2 May 14, 2014,

(19) 日本国特許庁(IP)	(12) 特許	公報	(82)	(11)特許番号 特許	, 第5492764号 (P5492764)
(45) 発行日 平成2	6年5月14日(2014.5	. 14)		(24) 登録日	平成26年3月	7日 (2014.3.7)
51) Int.Cl.		F I				
A61K 31/1	(2006.01)	A 6 1 K	31/18			
A 6 1 K 31/4	(2006.01)	A 6 1 K	31/40			
A 6 1 K 31/5	75 (2006.01)	A 6 1 K	31/5375			
A61K 45/00	(2006.01)	A 6 1 K	45/00			
A61P 27/00	(2006.01)	A 6 1 P	27/06			
				請求項の数 11	(全 30 頁)	最終頁に続く
21)出願番号	特願2010-504023	(P2010-504023)	(73)特許権:	者 509290599		
86) (22) 出願日	平成20年4月18日	ç ,	(10) 100110	ユニメッド フ	ファーマ、スポ	ール、エス、
65)公表番号	特表2010-524929	(P2010-524929A)		アールオー		
43) 公表日	平成22年7月22日	(2010.7.22)		スロバキア国	821 05	ブラチスラ
86)国際出願番号	PCT/SK2008/0500	05		バ、オリエスコ	DX 11	
87)国際公開番号	W02008/130332		(74)代理人	100064388		
87) 国際公開日	平成20年10月30日	E (2008.10.30)		弁理士 浜野	孝雄	
審査請求日	平成23年3月30日	(2011.3.30)	(74)代理人	100088236		
31)優先権主張番号	PP0054-2007			弁 理士 平井	煇一	
32) 優先日	平成19年4月20日	(2007.4.20)	(72)発明者	グレガン、フリ	ードリッヒ	
33)優先権主張国	スロバキア(SK)			スロバキア国	821 05	ブラチスラ
				バ,オリエスコ	バ 11	
			(72)発明者	レムコ、ミラン	/	
				スロバキア国	821 05	ブラチスラ



JP 5492764 B2 2014.5.14

言約古い始く

pharmaceuticals

バ、オリエスコバ 11

Acknowledgment

Dr. Claus-Wilhelm von der Lieth, (*1949 – †2007), German Cancer Research Center, Heidelberg, Germany

- Prof. Claudiu T. Supuran, Dr. A. Maresca, Università di Firenze, Dipartimento di Chimica, Italy
- Prof. Jozef Kožíšek, Dr. Jana Semanová, Dr.Peter Herich, Department of Physical Chemistry, Slovak University of Technology, Slovakia
- Dr. E. Slučiaková, Dr. J. Knapíková, Unimed Pharma Bratislava, Slovakia





